HIV Infections Clinical Trial
Official title:
Pre-operative Screening for HIV and Viral Hepatitis B and C: Pilot Study in Stomatology
The purpose of the OPDEP pilot study is to assess the feasibility of implementing a
pre-operative HIV / HCV / HBV screening proposal for all persons over 18 years of age and
refer for surgical intervention under general anesthesia in the Department of Stomatology of
the Pitié-salpêtrière hospital.
Patients undergoing treatment in Stomatology have particular areas at risk for the infections
we are looking for: young patients, precarious situation, drug use, migrants ...
The aim is to evaluate the conditions for a generalization of screening in the framework of
the preoperative assessment.
The HIV epidemic is still active in France, with 7 000 to 8 000 new infections per year.There
are an estimated 150,000 people living with HIV in France. Data from the hidden epidemic show
that:
- approximately 30,000 patients are unaware of their HIV status
- that the Ile de France area accounts for 44% of new infections. For over 20 years, the
patient-initiated HIV counseling and testing system has helped thousands of people to
know about their HIV status, but coverage for counseling and testing low. In 2007, WHO
and UNAIDS published guidance on provider-initiated HIV counseling and testing in health
facilities to improve acceptance and access to prevention, treatment And care.
It is in this context that, in France, the National Plan for the Fight against AIDS and
Sexually Transmitted Infections (STI) 2010-2014 recommended strengthening the screening
strategies, making it its Public Health dimension, Reintegrating into an overall preventive
approach. The expected benefits of routine screening would thus be individual as well as
collective: routine screening could be a means of controlling infection by modifying risk
behaviors, it could be a preventive tool by allowing earlier diagnosis Of the disease, it
could be associated with an evolution of the management and the prognosis of the infection by
allowing the initiation of an antiretroviral treatment in the acute phase of the infection.
In 2011, the Ministry of Health systematized the screening proposal to the entire population,
considering this strategy as cost-effective with a direct individual benefit and a Public
Health benefit by reducing the number of transmission. In this Plan, health authorities
recommend that hospital doctors and city general practitioners prescribe HIV testing much
more widely than they do, while targeting persons belonging to an identified risk group and
those Low "apparent" risk.
Screening remains a critical problem in the management with 20-30% of patients diagnosed at a
late stage (CD4 <200 / mm3).
According to the Institute of Health Watch, about 100 000 hepatitis C viral patients are
undiagnosed in France with differences in prevalence according to sex and age.
For hepatitis B, 55% of chronic carriers of the HBs antigen do not know their status, ie
about 160 000 people in France.
The recommendations of the 2014 expert report (Dhumeaux report) have changed screening not
only because of the high proportion of patients not aware of their serological status, but
also of recent advances in the treatment of these two infections.
For hepatitis C, the availability of more effective, better tolerated and shorter treatments
reinforces the need to screen, monitor and eventually treat the patient according to
treatment recommendations.
The expert report proposes to:
- Continue targeted screening based on the risk factors for contamination (drug addiction,
sexual exposure, originating from countries with high endemicity, etc.) and to inform
the general population and general practitioners
- Expand the screening strategies to the following populations: men aged 18 to 60,
pregnant women from the first prenatal consultation, by regularly evaluating these
strategies
- Associate in all cases the research of the three viruses HBV, HCV and HIV, taking into
account the epidemiological similarities, the possibility and the interest of grouped
tests.
The success of screening programs depends on a number of fundamental principles including:
- Targeted disease must be associated with high morbidity and mortality
- The screening test must be safe, acceptable and inexpensive
- Effective treatment must be available These 3 principles are just for HIV, viral
hepatitis B and C. HIV is associated with an increase in morbidity and mortality in the
absence of antiretroviral treatment. The serological test is safe, acceptable and
inexpensive. Antiretroviral therapy is available, and in 2015, French and international
guidelines provide universal treatment regardless of the stage of infection.
Hepatitis C is associated with increased morbidity and mortality in the absence of treatment.
The disease progresses to cirrhosis, hepatocellular carcinoma and terminal liver disease,
which are responsible for high morbidity and may also be associated with severe extrahepatic
manifestations. A serological test is available, safe, acceptable and inexpensive. The
antiviral treatment is available with new strategies and new molecules allowing a cure in
more than 95% of the patients according to the stage of the disease.
Hepatitis B is associated with increased morbidity and mortality in the absence of treatment.
The serological test is safe, acceptable and inexpensive. The disease progresses to
cirrhosis, hepatocellular carcinoma and terminal liver disease, which are responsible for
high morbidity. Antiviral treatment is available and helps control long-term infection.
These 3 pathologies, targets of our screening, respond to these fundamental principles.
The investigators hypothesize that pre-operative screening will increase the number of
HIV-positive people screened and decrease the number of people who have been treated late for
their HIV, HBV and / or HCV infection. The persons detected in this way could be taken care
of in optimal care channels more precisely. Moreover, knowledge of their seropositivity
should modify their behavior and favor the rupture of the transmission. The proposed
methodology is based on the development of a screening strategy for HIV and B and C viral
hepatitis by serology, which is systematically proposed by the anesthesiologist to all
persons over the age of 18 who are undergoing surgery under anesthesia In Stomatology. This
study is based on the formalization of close and effective functional links between the
Department of Infectious Diseases and Tropical Diseases, the Department of Stomatology and
the Laboratory of Virology.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |